HENDERA
831152
Hengerda New Materials
300946
Fujian Nebula Electronics.,Ltd
300648
4
Cubic Digital Technology
300344
5
HNAC Technology
300490
US Stock MarketDetailed Quotes
CNTX Context Therapeutics
- 0.8216
- +0.0156+1.94%
Close Feb 14 16:00 ET
73.70MMarket Cap-0.93P/E (TTM)
0.8338High0.7900Low41.73KVolume0.7900Open0.8060Pre Close34.13KTurnover0.11%Turnover RatioLossP/E (Static)89.70MShares2.750052wk High0.88P/B32.00MFloat Cap0.770052wk Low--Dividend TTM38.95MShs Float10.8700Historical High--Div YieldTTM5.43%Amplitude0.4700Historical Low0.8170Avg Price1Lot Size
Context Therapeutics Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you do...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you do...
36
6
5
$Context Therapeutics (CNTX.US)$ good buy price
$Quantum Computing (QUBT.US)$ $EZGO Technologies (EZGO.US)$ $Exicure (XCUR.US)$ $Context Therapeutics (CNTX.US)$ $Energy Vault (NRGV.US)$ $Galaxy Payroll (GLXG.US)$ $CLICK Holdings (CLIK.US)$ $D-Wave Quantum (QBTS.US)$ $Li Bang International (LBGJ.US)$ $908 Devices (MASS.US)$ $Safe & Green Development (SGD.US)$ $Oncolytics Biotech (ONCY.US)$ $Helius Medical Technologies (HSDT.US)$ $Millennium Group International (MGIH.US)$ $Vision Marine Technologies (VMAR.US)$ $Safe & Green (SGBX.US)$
📊⚡️📊
📊⚡️📊
3
5
$Context Therapeutics (CNTX.US)$
CTIM-76's development targets a significant unmet need in CLDN6-positive cancers. The bispecific antibody's mechanism of action, engaging T cells to target CLDN6-expressing tumor cells, represents a sophisticated approach in immuno-oncology. Recent SITC presentation data supporting the first-in-human dose selection indicates robust preclinical validation.
For investors, thi...
CTIM-76's development targets a significant unmet need in CLDN6-positive cancers. The bispecific antibody's mechanism of action, engaging T cells to target CLDN6-expressing tumor cells, represents a sophisticated approach in immuno-oncology. Recent SITC presentation data supporting the first-in-human dose selection indicates robust preclinical validation.
For investors, thi...
1
$Context Therapeutics (CNTX.US)$
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Tuesday, 14th January at 4:58 pm
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers
Trial marks key milestone in driving pipeline progress
PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today anno...
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Tuesday, 14th January at 4:58 pm
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers
Trial marks key milestone in driving pipeline progress
PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today anno...
2
$Context Therapeutics (CNTX.US)$ On December 23, 2024, Context Therapeutics Inc. (the “Company”) sold 14,705,882 shares of its common stock, for aggregate gross proceeds of approximately $15 million. The shares were sold pursuant to a sales agreement with Leerink Partners LLC (the “Agent”) dated December 2, 2024. The Agent has informed the Company that the shares were purchased by MPM BioImpact LLC.
1
2
$Context Therapeutics (CNTX.US)$ need volume
$Context Therapeutics (CNTX.US)$ $22nd Century (XXII.US)$ $LakeShore Biopharma (LSB.US)$ $ShiftPixy(Delisted) (PIXY.US)$ $Cyclacel Pharmaceuticals (CYCC.US)$ $Phunware (PHUN.US)$ $Spirit Airlines (SAVE.US)$ $Stride (LRN.US)$ $Zapata Computing (ZPTA.US)$ $Farmmi (FAMI.US)$ $Mustang Bio (MBIO.US)$ $DBV Technologies (DBVT.US)$ $CNS Pharmaceuticals (CNSP.US)$
9
No comment yet
Trending Stocks
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve
Moo Earnings
Feb 2 12:39
AMZN earnings preview: Grab rewards by guessing the opening price!
Golden Goose : How do you think Trumps new tarrifs on Canada will affect FMST?
Lynn953818 : thank you very much
Jaguar8 OP Golden Goose : Since the U.S. imports lithium from Canada, any tariffs imposed would likely be reflected in one of two ways: either the cost is added to the price of lithium when it leaves Canada, or U.S. companies importing it will absorb the expense. While tariffs generate revenue for the government, the added costs will ultimately trickle down to consumer goods in the U.S. It’s important to note that Canada supplies 56% of the lithium used in the U.S. This means products that rely on lithium—such as batteries and certain pharmaceuticals—could see price increases if tariffs are applied.
Golden Goose Jaguar8 OP : thanks dude
TerryJinn : QSI, please give me a little push
View more comments...